FDA Requires GLP-1 Drug Labels to Disclose Potential NAION Risk

The FDA is requiring every glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicine to disclose a potential increase in NAION risk, a rare disorder that can abruptly affect sight in one eye without pain.

The Nov. 9, 2026, requirement covers the full drug class, including medicines used for diabetes, weight loss and other approved purposes. NAION can cause permanent vision loss. The labeling change addresses a potential increase in the risk of the condition.